Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kalvista Pharmaceuticals Inc (NQ: KALV )

10.77 +0.20 (+1.89%)
Streaming Delayed Price Updated: 10:17 AM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kalvista Pharmaceuticals Inc

< Previous 1 2 3 Next >
FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial
The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life... 
Via Benzinga
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the... 
Via Talk Markets
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Kalvista Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Kalvista Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
31 Stocks Moving In Tuesday's Mid-Day Session
Gainers MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) gained 20.8% to $5.32 after dropping more than 10% on Monday. Takung Art Co., Ltd. (NASDAQ: TKAT) shares surged 18.2% to $21.08... 
Via Benzinga
Why Crispr, KalVista And Syndax Are Moving Today
CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma... 
Via Benzinga
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824
Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.